Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Method of culturing cells in suspension
Patent
1995-06-06
1998-12-08
Elliott, George C.
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Method of culturing cells in suspension
435325, 435386, 424 931, 424 937, 424 9371, C12N 506, A61K 4500
Patent
active
058468277
ABSTRACT:
Methods for activating cytotoxic T lymphocytes (CTL) in vitro are presented in conjunction with methods for using the activated CTL for therapy in vivo. Additionally, a method for killing specific CTL in vivo is presented using antigen presenting cells which were modified in vitro.
REFERENCES:
patent: 5081029 (1992-01-01), Zarling et al.
Klimas et al., AIDS 8:1073-1081 (1994).
Riddell et al., Annu. Rev. Immunol. 13:545-586 (1995).
Hsueh et al., Cellular Immunology 159:271-279 (1994).
D. Torpey III et al. (1993) Clinical Immunology and Immunopathology 68(3):263-272.
Clerici, et al., "Detection of Cytotoxic T Lymphocytes Specific for Synthetic Peptides of gp160 in HIV-Seropositive Individuals," J. Immunol. , 146(7):2214-2219 (Apr. 1, 1991).
Koenig, et al., "Determination of epitopes recognized by HIV-specific TL," Int. Conf. AIDS (Canada) (4-9 Jun. 1989), 5:531, abstract No. W.C.O. 41 (1989).
Lee et al., Hematology/Oncology Clinics of North America 8(6):1203-1221 (1994).
Fox, Bio/Technology 12:128 (1994).
Epperson, D.E. et al., "Cytokines Increase Transporter in Antigen Processing-1 Expression More Rapidly than HLA Class I Expression in Endothelial Cells," J. Immunology, 149(10):3297-3301 (15 Nov. 1992).
Smith, J.D., et al., "Extensive peptide ligand exchange by surface class I major histocompatibility complex molecules independent of exogenous .beta..sub.2 -microglobulin," Proc. Natl. Acad. Sci USA, 89:7767-7771 (Aug. 1992).
Van Bleek, G.M., et al., "Isolation of an endogenously processed immunodominant viral peptide from the class I H-2K.sup.b molecule," Nature, 348:213-216 (15 Nov. 1990).
Greenberg, P.D., "Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells," Advances in Immunology, pp. 281-355 (Jun. 1990).
Riddell, S.R., et al., "Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones," Science, 257:238-241 (10 Jul. 1992).
Kantor, J., et al., "Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus Vaccine," J. Nat'l. Cancer Institute, 84(14):1084-1091 (15 Jul. 1992).
Ioannides, C.G., et al., "T-Cell Recognition of Oncogene Products: A New Strategy for Immunotherapy," Molecular Carcinogenesis, 6:77-82 (1992).
Rosenberg, S.A., "Immunotherapy of Cancer Using Interleukin 2: Current Status and Future Prospects," Immunology Today, 9(2):58-61 (1988).
Callard, R.E., et al., "CD19 Regulation of Human B Cell Responses," J. Immunology, 148(10):2983-2987 (15 May 1992).
Sakane, T., et al., "Protein A from Staphylococcus aureus--A Mitogen for Human T Lymphocytes and B Lymphocytes but not L Lymphocytes," J. Immunology, 120(1):302-311 (Jan. 1978).
Falkoff, R.J.M., et al., "Separate Signals for Human B Cell Proliferation and Differentiation in Response to Staphylococcus aureus: Evidence for a Two-Signal Model of B Cell Activation," J. Immunology, 129(1);97-102 (Jul. 1982).
Pryjma, J., et al., "Induction and Suppression of Immunoglobulin Synthesis in Cultures of Human Lymphocytes: Effects of Pokeweed Mitogen and Staphylococcus aureus Cowan I," J. Immunology, 124(2):656-661 (Feb. 1980).
Bjorkman, P.J., et al., "Structure of the human class I histocompatibility antigen, HLA-A2," Nature, 329:506-512 (8 Oct. 1987).
Bjorkman, P.J., et al., "The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens," Nature, 329:512-518 (8 Oct. 1987).
Falk, K., et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," Nature, 351:290-296 (23 May 1991).
Lamb, J.R., et al, "T-Cell Recognition of Influenza Viral Antigens," Human Immunology, 19:79-89 (1987).
De Bruijn, M.L.H., et al., "Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses," Eur. J. Immunol., 21:2963-2970 (1991).
Parham, P., "Transporters of Delight," Nature, 348:674-675 (20/27 Dec. 1990).
Kos, F.J., et al., "Induction of primary anti-viral cytotoxic T cells by in vitro stimulation with short synthetic peptide and interleukin-7," Eur. J. Immunol., 22:3183-3185 (1992).
Alderson, M.R., et al., "Interleukin 7 Enhances Cytolytic T Lymphocyte Generation and Induces Lymphokine-activated Killer Cells from Human Peripheral Blood," J. Exp. Med., 172:577-587 (Aug. 1990).
Guilhot, S., et al., "Hepatitis B Virus (HBV)-Specific Cytotoxic T-Cell Response in Humans: Production of Target Cells by Stable Expression of HBV-Encoded Proteins in Immortalized Human B-Cell Lines," J. Virology, 66(5):2670-2678 (May 1992).
Azuma, M., et al., "CD28 Interaction with B7 Costimulates Primary Allogeneic Proliferative responses and Cytotoxicity Mediated by Small, Resting T Lymphocytes," J. Exp. Med., 175:353-360 (Feb. 1992).
Harding, F.A., et al., "CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones," Nature, 356:607-609 (16 Apr. 1992).
Linsley, P.S., et al., "Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation," J. Exp. Med., 173:721-730 (Mar. 1991).
Schwartz, R.H., "A Cell Culture Model for T Lymphocyte Clonal Anergy," Science, 248:1349-1356 (15 Jun. 1990).
Zhou, X., et al., "In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides," J. Immunological Methods, 153:193-200 (1992).
Nikolic-Zugic, J., et al., "Peptide Presentation by Class-I Major Histocompatibility Complex Molecules," Immunol. Res., 10:54-65 (1991).
Madden, D.R., et al., "The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation," Nature, 353:321-324 (26 Sep. 1991).
Kubitscheck, U., et al., "Peptide Binding to Class I Molecules of the Major Histocompatibility Complex on the Surface of Living Target Cells," Scand J. Immunol., 36:341-348 (1992).
Sugawara, S., et al., "A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3," J. Immunological Methods, 100:83-90 (1987).
Rotzschke, O., et al., "Naturally-occurring peptide antigens derived from the MHC class-I-restricted processing pathway," Immunology Today, 12(1):447-453 (1991).
Sette, A., et al., "Peptide Binding to HLA Class I Molecules Measured by a Quantitative Molecular Binding Assay," Cell, 74:1-9 (10 Sep. 1993).
Mamula, M.J., et al., "Do B cells drive the diversification of immune responses?" Immunology Today, 14(4):151-152 (1993).
Saiki, O., et al., "Synergistic Effects of Human B and T Lymphocyte Mitogens Induce Uniform, High Levels of Immunoglobulin Secretion Among Normal Donors," J. Immunological Methods, 45:221-226 (1981).
Hoffenbach, A., et al., "Unusually High Frequencies of HIV-Specific Cytotoxic T Lymphocytes in Humans," J. Immunology, 142(2):452-462 (15 Jan. 1989).
Celis Esteban
Kubo Ralph
Serra Horacio
Tsai Van
Wentworth Peggy
Cytel Corporation
Elliott George C.
Railey II Johnny F.
LandOfFree
Methods for ex vivo therapy using peptide-loaded antigen present does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for ex vivo therapy using peptide-loaded antigen present, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for ex vivo therapy using peptide-loaded antigen present will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-176623